A Game-Changing Test in the Fight Against Esophageal Cancer
This is the game that TissueCypher is changing. Rather than have physicians make educated guesses about an individual patient ...
来自MSN7 小时
Eduin Caz, leader of Grupo Firme, at risk of developing esophageal cancer
The singer mentioned that his hiatal hernia got complicated, leading to Barrett's esophagus and subsequently cancer ...
Stocktwits on MSN6 小时
Bristol Myers Squibb Stock In Focus After FDA Approves Cancer Drug: Retail Sentiment Brightens
Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...
Cure Today1 天
FDA Approves Tevimbra Plus Chemo for Gastric, Gastroesophageal Junction Adenocarcinoma
Earlier this year, the agency approved Tevimbra for the treatment of patients with unresectable, metastatic esophageal cancer ...
Pharmaceutical Technology2 天
CBP-1019 by Coherent Biopharma for Esophageal Cancer: Likelihood of Approval
CBP-1019 is under clinical development by Coherent Biopharma and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition ...
HealthDay on MSN9 天
Global Burden of Esophageal Cancer Remains Considerable
The burden of esophageal cancer (EC) remains substantial worldwide, with an upward trend seen in age-related EC bur ...
Jill Jacobson’s Health: About Her Cancer Battle Before Death
Jacobson died at the age of 70 in December 2024 after battling a ‘long illness,’ her friend and publicist confirmed.
Pharmaceutical Technology2 天
LM-302 by Bristol-Myers Squibb for Adenocarcinoma Of The Gastroesophageal Junction ...
LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.